Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes

What Was Tested

This randomized controlled trial paper looks at Exenatide.

To explore the effects of dual therapy with dapagliflozin and exenatide on body weight, body composition, glycaemic variables and systolic blood pressure (SBP) in obese adults without diabetes.

MRI was used to assess change in body composition.

Who Took Part

The abstract describes 50 adults taking part.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Participants were instructed to follow a balanced diet and exercise moderately.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Exenatide study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Exenatide group a baseline to be compared against.

What Was Measured

The subject headings attached to it are Adipose Tissue, Benzhydryl Compounds, Blood Glucose, Blood Pressure, Body Composition, Exenatide and Glucose Intolerance.

The authors tagged it with the keywords dapagliflozin, obesity and prediabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exenatide in 50 adults.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Exenatide compound page, all human trials.